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Percutaneous coronary intervention (PCI) has become a mainstay in the treatment of patients
with coronary artery disease. Currently, more than one million coronary angioplasty and stent
implantation procedures are performed annually. Although increasingly complex lesions and
higher risk patients are being successfully treated percutaneously, restenosis and disease
progression continue to cause significant morbidity. Restenosis occurs in approximately
one-third of patients, one-half of who remain asymptomatic, while disease progression occurs
at rates approaching 7% per year. Despite technological advances, unadjusted mortality rates
have actually increased since the mid-1980s, and the current annual risk of a major adverse
cardiac event following PCI is 5% to 7%. Although randomized clinical trials are needed to
more definitively show a benefit, when performed six or more months following PCI,
myocardial perfusion imaging reliably identifies patients most at risk of a poor long-term
outcome. Directed reintervention can have a salutary impact on the prognosis of these
patients. In view of recent data showing a positive impact of imaging and reintervention in
patients after PCI, current guidelines should be reassessed. (J Am Coll Cardiol 2004;43:
328–36) © 2004 by the American College of Cardiology Foundation
Cardiovascular disease is the leading cause of morbidity and
mortality in industrialized nations, and caused 39.4% of all
deaths in the U.S. in 2000 (1). Coronary artery disease
(CAD) is the most prevalent form of cardiovascular disease,
affecting 12.9 million Americans. The impact of CAD on
the health of individuals in the developed world has de-
clined over the past three decades as a result of the
identification of modifiable risk factors and the introduction
of new primary and secondary prevention strategies. None-
theless, CAD continues to be a major public health problem.
Percutaneous treatment of CAD began in 1977, when
Gru¨ntzig et al. (2) introduced percutaneous transluminal
coronary angioplasty (PTCA). In the mid 1990s, publica-
tion of two multicenter trials (3,4) demonstrating improved
outcomes led to widespread use of stents, while develop-
ment of new antiplatelet agents (5) resulted in even fewer
complications following percutaneous coronary intervention
(PCI). As a result, the use of, and indications for, PCI have
greatly expanded, such that transcatheter revascularization is
now routinely performed in patients with acute myocardial
infarction (MI) and unstable coronary syndromes, and is
increasingly employed to treat complex lesions, small-
diameter vessels, chronic total occlusions, and diseased
bypass conduits. For many patients with multivessel disease,
PCI is an alternative to coronary artery bypass grafting
(CABG) (6). More than one million PCI procedures were
performed in the U.S. in 2000 (1). In contemporary
practice, approximately 70% of PCI procedures involve
placement of a stent (7). The number of transcatheter
interventions is likely to increase further as the population
ages and as increasingly complex lesions and more cases of
multivessel disease are treated with PCI rather than surgery.
Although long-term outcome following PCI is good
(6,8,9), a comparison of the 1997 to 1998 Dynamic Registry
and the 1985 to 1986 National Heart, Lung, and Blood
Institute Registry (10) of patients undergoing an initial PCI
procedure revealed that, despite higher procedural success
rates, one-year crude mortality was higher for patients in the
Dynamic Registry (5.4% vs. 3.6%; p  0.05), particularly
among women (7.6% vs. 4.4%; p  0.05). Increased
mortality resulted from inclusion of more patients 65
years of age, more patients with diabetes and congestive
heart failure, treatment of more total occlusions and vein
graft lesions, and other “circumstances of the procedure.”
There was no difference in outcome between patients who
received stents and those who did not.
In the multicenter Lescol Intervention Prevention Study
(11), the annual risk of a major adverse cardiac event,
defined as cardiac death, nonfatal MI, or a reintervention
procedure (CABG, repeat PCI, or PCI for a new lesion)
approached 7%, whereas the annual risk of a hard event
(cardiovascular death or nonfatal MI) was 2% in the placebo
group over 3.9 years of follow-up. Although statin therapy
improved outcome, the annual adverse event rate remained
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5% whereas the hard event rate remained 1% in treated
patients.
Hachamovitch et al. (12) showed that among patients
with normal myocardial perfusion imaging (MPI), those
with a history of CAD have a higher annual hard event rate
(cardiac death or nonfatal MI) than patients without such a
history (1.4% vs. 0.4%; p 0.001). Furthermore, the risk of
a hard event increases with time for patients with CAD,
whereas the risk is uniform for those without CAD.
RESTENOSIS AND DISEASE PROGRESSION
Restenosis has been defined in numerous ways, making
comparisons between restenosis rates problematic. None-
theless, restenosis remains the Achilles heel of PCI
(4,13–22) and, however defined, remains a major clinical
problem (Table 1). In addition, progression of disease at
untreated sites occurs at rates approaching 7% per year
(23,24). When restenosis does occur, it usually happens
within three to nine months (14,25,26). Patients with
symptomatic restenosis generally develop angina within four
to five months of PCI (13). Angina developing after nine
months is usually due to progression of disease at another
site (23,27). Approximately 50% of patients remain asymp-
tomatic when restenosis occurs (Table 1). Conversely, up to
45% of patients developing chest pain after PCI do not have
angiographic restenosis (13).
Most of the factors associated with restenosis (8,13,
16,22,26,28–31) are listed in Table 2. Although stents
decrease restenosis (3,4,17,18,22), deployment of stents in
high-risk lesions has led to in-stent restenosis (ISR) rates as
high as 58% (8,9,18,31). In 1999, approximately 150,000
patients in the U.S. developed ISR (31). Although drug-
eluting stents and intracoronary brachytherapy may prevent
or treat ISR, the long-term efficacy of these technologies is
unproven (9,31–33).
Asymptomatic restenosis. Several investigators (13–16,
22,34) have shown that chest pain following PCI is a poor
indicator of restenosis (Table 3). Asymptomatic restenosis
occurs in 18% to 59% of patients following PTCA and in
30% to 58% of patients after stenting (Table 1). Angio-
graphic factors associated with asymptomatic restenosis
include severe or totally occlusive target lesions (35), pres-
ence of collateral vessels (35,36), left anterior descending
artery lesions (37), single-vessel disease (16,36), more com-
plete revascularization (16,37), and larger reference vessel
diameter (22).
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CAD  coronary artery disease
ECG  electrocardiography
ISR  in-stent restenosis
MI  myocardial infarction
MPI  myocardial perfusion imaging
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary
angioplasty
SPECT  single-photon emission computed tomography
Table 1. Restenosis Following Percutaneous Coronary Intervention
Author (Ref.) Year
Patients
Studied
Intervention
Performed
Follow-Up
Angiogram
Restenosis
Rate
Asymptomatic
Restenosis
Holmes et al. (13) 1984 557 PTCA 6 months 34%* 24%
Nobuyoshi et al. (14) 1988 229 PTCA 6 months 49%† 59%
Hecht et al. (15) 1991 116 PTCA 6 months 60%‡ 36%
Herna´ndez et al. (16) 1992 839 PTCA 6–9 months 33%§ 48%
Fischmann et al. (4) 1994 159 PTCA 6 months 42% N/A
177 Stent 6 months 32% N/A
Versaci et al. (17) 1997 46 PTCA 12 months 40%§ 18%
49 Stent 12 months 19%§ 36%
Betriu et al. (18) 1999 199 PTCA 6 months 37%§ 46%¶
198 Stent 6 months 22%§ 30%¶
Wehinger et al. (19) 1999 1,867 Stent 6 months 33% N/A
Kastrati et al. (20)# 2000 163 PTCA 6 months 38% N/A
171 Stent 6 months 36% N/A
Mudra et al. (21)** 2001 457 Stent 6 months 24% N/A
Ruygrok et al. (22) 2001 1,221 PTCA 6 months 31% 53%
1,469 Stent 6 months 16% 58%
Overall restenosis rate and rate of asymptomatic restenosis 30%†† 47%††
Restenosis rate and rate of asymptomatic restenosis following PTCA 35%†† 45%††
Restenosis rate and rate of asymptomatic restenosis following coronary stenting 26%†† 53%††
*Restenosis defined as either an increase of at least 30% from immediate post-PTCA stenosis or a loss of at least 50% of the gain achieved at PTCA, assessed by conventional
angiography; †restenosis defined as 50% loss of the gain in absolute stenotic diameter assessed by cinevideodensitometry; ‡restenosis defined as return of a previously dilated
vessel to 50% diameter reduction, assessed by magnified electronic caliper measurements; §restenosis defined as stenosis 50% or 50% in previously dilated vessel segment,
assessed by conventional angiography; restenosis defined as 50% or 50% diameter stenosis at treated vessel segment, assessed by quantitative coronary angiography; ¶assumes
all patients with recurrent angina had restenosis; #study conducted in small (2.0 to 2.8 mm diameter) vessels; **33 lesions (7% of all stented lesions) were recurrent stenoses;
††weighted average.
N/A  data not available; PTCA  percutaneous transluminal coronary angioplasty.
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Several investigators (16,22) found that symptomatic
status is related to the severity of the recurrent lesion.
Others (35–37) observed no such correlation. Minimal
lumen diameter rather than stenosis severity may be more
predictive of angina (34). Some have found that neither
angina status before PCI (22,37,38) nor diabetes mellitus
(16,22,34,37,38) is correlated with symptomatic status. The
converse was noted by others (9). Both the presence (22)
and absence (16) of unstable angina at presentation, and
both younger (36) and older age (15) have been associated
with asymptomatic restenosis. Because no meta-analysis of
the interaction among clinical and angiographic factors and
symptomatic status has been performed, there is no reliable
method of predicting which patients are most at risk of
developing asymptomatic restenosis and silent ischemia
following PCI. Using a logistic regression model, Zellweger
et al. (38) found that the only independent predictor of
silent ischemia after coronary stenting was a less extensive
and severe ischemic defect on MPI performed six months
after revascularization.
However, of those factors that have been associated with
asymptomatic restenosis, diabetes mellitus, unstable angina,
and severe or totally occlusive target lesions were more
prevalent in patients in the 1997 to 1998 Dynamic Registry
than in patients in the 1985 to 1986 registry (10). Thus, in
contemporary practice, more patients are likely to remain
asymptomatic when restenosis occurs.
The prognostic significance of silent ischemia following
PCI is unclear. Although some studies (16,35) demon-
strated a favorable prognosis for patients with asymptomatic
restenosis, more recent studies (36,38,39) found such pa-
tients to be at increased risk for adverse events.
Herna´ndez et al. (16) followed 839 PTCA patients who
underwent electrocardiography (ECG) stress testing and
angiography at six to nine months. Of the 277 patients with
restenosis, 48% were asymptomatic. During the 17 months
of follow-up, there were 81 repeat PTCAs, 11 CABGs, and
6 deaths in the symptomatic cohort. There were no CABGs
or deaths in asymptomatic patients. However, of the 77
patients with asymptomatic restenosis who had a positive or
nondiagnostic stress test, 24 underwent reintervention. In
all, 18% of asymptomatic patients underwent repeat PCI,
which undoubtedly favorably influenced the outcome of this
group. The authors concluded that “asymptomatic resteno-
sis is a frequent phenomenon with a good prognosis mainly
in patients with a negative exercise test result.”
Table 3. Chest Pain as a Marker of Restenosis Following Percutaneous Coronary Intervention
Author (Ref.) Year
Patients
Studied
Follow-Up
Angiogram Sens % Spec % PPV % NPV % Acc %
Holmes et al. (13) 1984 524 6 months 79 68 56 86 72
Nobuyoshi et al. (14)* 1988 229 6–12 months 41 95 91 59 66
Hecht et al. (15) 1991 116 6 months 64 34 59 39 52
Herna´ndez et al. (16)† 1992 839 6–9 months 52 N/A N/A N/A N/A
Legrand et al. (34) 1997 325 6 months 56 86 51 89 80
Ruygrok et al. (22) 2001 2,690 6 months 45 N/A N/A N/A N/A
Overall performance of chest pain as a marker of restenosis 51‡ 75‡ 62‡ 77‡ 71‡
Data reflect six-month symptom status and angiographic findings, unless otherwise indicated; *one-year data; †six-to-nine-month data; ‡weighted average.
Acc  accuracy; N/A  data not available; NPV  negative predictive value; PPV  positive predictive value; Sens  sensitivity; Spec  specificity.
Table 2. Factors Associated With Restenosis
Clinical Factors Angiographic Factors
Absence of prior myocardial infarction (26,29) Branch vessel lesion (29)
Continued smoking (26,29) Bypass graft lesion (13,28,29,31)
Diabetes mellitus (8,13,26,29,31) Chronic, totally occlusive lesion (28,29,31)
Elevated blood insulin levels (29) Extensive dissection (28,29)
Male gender (13,16,22,26,28,29) Final translesional gradient 15–20 mm Hg (13,29)
Prior restenosis (31) Greater final diameter stenosis (8,26,29)
Severe angina at presentation (13,26) Greater length of stented segment (31)
Unstable angina (8,13,26,28,29) Greater severity of initial stenosis (13,26)
Vasospastic angina (28) Implantation of multiple stents (30,31)
Initial translesional gradient 40 mm Hg (13)
Left main coronary artery lesion (28)
Long lesion (26,29,30)
Ostial lesion (29,31)
Multiple lesions (28)
Presence of thrombus (29)
Proximal anterior descending artery lesion (26,28,29)
Restenotic lesion (8,28)
Smaller final minimal lumen diameter (8,31)
Smaller reference vessel diameter (8,26,30,31)
Suboptimal final result (28)
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Cottin et al. (39) followed 152 coronary stent patients.
Single-photon emission computed tomography (SPECT)
performed five months after stenting showed reversible
perfusion defects in 47 patients; ischemia was silent in 70%.
Adverse events (MI or death) occurred in 28% of patients
with ischemia, including death in 15%, but in only 3% of
patients without ischemia. Angina was not an independent
predictor of adverse events.
Zellweger et al. (38) prospectively followed 356 patients
who underwent coronary stenting and routine SPECT
imaging six months thereafter for four years. Eighty-one
patients had target vessel ischemia, which was silent in
62%. Sixteen patients with target vessel ischemia who
underwent MPI-driven repeat revascularization within 60
days of imaging were excluded from the “prognostic patient”
group; the extent and severity of ischemia in these 16
patients were greater than in the 65 patients with ischemia
included in the prognostic group. Among patients in the
prognostic group, the composite end point (death, nonfatal
MI, and late revascularization) occurred more frequently in
patients with ischemia than in those without ischemia
(cumulative event rate 38% vs. 17%; p 0.001), although
this difference was driven mainly by repeat revasculariza-
tion. The extent and severity of ischemia determined by
MPI, not symptom status, were the best predictors of
outcome. Patients with silent target-vessel ischemia tended
to have less extensive and severe ischemia than symptomatic
patients, and although they also tended to have better
event-free survival (event rate  32% vs. 52%; p  NS),
patients with silent target vessel ischemia fared worse than
patients with no ischemia (32% vs. 17%; p  0.01). An
additional 32 patients with ischemia in an untreated vascular
territory, 59% of who were asymptomatic, were also ex-
cluded from the prognostic patient group. The event rate in
these patients (cumulative event rate  28%) was similar to
that in patients with target-vessel ischemia included in the
prognostic patient group (overall cumulative event rate 
38%).
Disease progression. Following PCI, progression of dis-
ease in untreated vessel segments occurs at rates approach-
ing 7% per year in both symptomatic and asymptomatic
patients (23,24). More than one-half of patients presenting
with chest pain more than one year after PCI have a new
obstructive lesion or significant worsening of a previously
nonobstructive stenosis (27). During late follow-up, out-
comes are more strongly correlated with disease progression
than disease recurrence (40).
Kober et al. (24) performed angiography on 87 patients
more than two years after PTCA. Significant disease at an
untreated site was evident in 44%. Importantly, 45% of
asymptomatic patients had obstructive lesions. In an angio-
graphic study of patients presenting with angina or acute
MI more than one year after PCI (25), significant disease
progression was found in 57%.
USE OF NONINVASIVE TESTING
Appropriate use of noninvasive testing following PCI has
never been systematically investigated. Thus, it is not
surprising that physicians’ practice patterns vary widely (41).
While acknowledging that myocardial ischemia, whether
painful or silent, worsens prognosis, current guidelines
(29,42,43) and several authors (44,45) recommend against
routine testing of asymptomatic patients. Others (36,46)
argue that all patients should undergo MPI following PCI,
citing data demonstrating adverse outcomes in asymptom-
atic patients with ischemia.
Although there have been case reports of acute occlusion
following coronary angioplasty and stenting, occurring in
association with stress testing (47), multiple investigators
have shown that stress testing early after PCI is safe
(48–53). Exercise ECG has repeatedly been demonstrated
to be inaccurate in detecting restenosis following revascu-
larization (13,15,16,34,36,37,54). In contrast, the sensitivity
and specificity of MPI, performed at varying times after
PCI, range from 39% to 100% and 46% to 100%, respec-
tively (15,26,37,45,54–59), improving with time since re-
vascularization (Table 4).
Myocardial perfusion imaging early after PCI. A de-
crease in specificity has been observed when MPI is
performed within two months of PCI. This phenomenon
was initially noted following PTCA in the early days
of PCI (49,50,53,60), and has been observed more recently
in studies using MPI shortly after coronary stenting (48,
51,52,61). Reversible perfusion defects were seen in 18% to
45% of asymptomatic patients using planar MPI
1 day to 7 weeks after coronary angioplasty (49,60) and in
35% of patients undergoing dipyridamole SPECT within
19 days of coronary angioplasty (53). Rode´s-Cabau et al.
(48) detected reversible defects in 17% of patients who
underwent exercise stress SPECT within one week of
stenting. Nagaoka et al. (51) observed reversible defects in
36% of patients four days after stenting using adenosine
SPECT, which persisted in 50% of patients who underwent
repeat imaging at 1.5 months.
The incidence of restenosis is 52% to 75% in patients
with reversible defects on early imaging, compared with an
incidence of 12% to 17% in those with normal perfusion
(48,49). This observation prompted some (49,60,62) to
contend that MPI performed early after PCI can “predict”
future restenosis. Others (63) argue that “stress testing
probably does not predict which patients are at risk of
developing restenosis, but rather identifies those in whom
restenosis has already occurred at the time of stress testing.”
Bachmann et al. (61) observed reversible perfusion de-
fects in the treated vascular territory within 48 h of
angiographically successful PCI in 54% of patients follow-
ing PTCA or atherectomy, and in 43% of patients after
coronary stenting (p  NS). Using intracoronary ultra-
sound, they found that although such defects were associ-
ated with greater residual stenoses and higher plaque bur-
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dens, there was significant overlap of residual stenosis values
between patients with and those without perfusion defects.
Thus, they concluded that there are “additional mechanisms
capable of impairing myocardial blood flow” and cite endo-
thelial dysfunction as a possible cause of perfusion defects
following PCI.
The ability of stress MPI to detect epicardial coronary
disease depends upon regional differences in tracer uptake
occurring as a consequence of impaired relative coronary
flow reserve, the ratio of maximal blood flow in stenotic
arteries to maximal flow in patent arteries. However, myo-
cardial perfusion, and thus MPI, also depends upon micro-
vascular function. Regional hypoperfusion can occur in the
absence of coronary obstruction if absolute myocardial flow
reserve, the ratio of blood flow during maximal vasodilation
to blood flow under resting conditions, is impaired. Early
after PCI, absolute coronary flow reserve is diminished
(62,64,65). Thus, even in the presence of a patent artery,
regional perfusion can be impaired by endothelial dysfunc-
tion and medial injury at the treated site and/or abnormal
microvascular and resistive vessel function distal to the site
(64,65).
Myocardial perfusion imaging late after PCI. Eight stud-
ies involving 640 patients, in which stress SPECT and
coronary angiography were performed within 2 to 48
months of PCI, are listed in Table 4. The overall sensitivity
and specificity of SPECT for detecting myocardial ischemia
two or more months after PCI are both 79%, and are
roughly equivalent in all three vascular territories (15,54).
Manyari et al. (50) performed a longitudinal study,
assessing patients with planar MPI nine days, three months,
and seven months following PTCA. Forty percent of
defects observed early after PCI improved two to nine
months later. At seven-month angiographic follow-up, no
patient had restenosis. In another serial imaging study,
Versaci et al. (52) performed stress planar imaging within
24 h of PCI. Reversible defects were observed in 100% of
PTCA patients and in 44% of stented patients. At six-
month follow-up, 60% of PTCA patients without angio-
graphic restenosis had persistent defects; no patients in the
stent cohort had restenosis or a perfusion defect.
Among patients without known CAD, but with low-to-
intermediate likelihood of disease, the rate of cardiac death
or MI is 0.6% per year for those with normal SPECT, 1.4%
for those with one or two abnormal segments, and 2.1% per
year for those with three or more abnormal segments (66).
Less is known about the prognostic value of MPI following
PCI. In the Angioplasty Compared to Medicine Study (67),
328 patients were randomized to PTCA or medical therapy.
At six months, 270 patients underwent stress MPI and were
followed for a minimum of five years thereafter. Mortality
in the PTCA cohort was 20% for those with a reversible
defect versus 7% for those without such a defect (p  0.03).
By multivariate analysis, the strongest predictors of mor-
tality were diabetes, smoking, and a reversible perfusion
defect.
Alazraki et al. (68) assessed the prognostic value of
SPECT among 165 patients who underwent PCI for
multivessel disease as part of the Emory Angioplasty Versus
Surgery Trial. At least 43% of the 76 PCI patients with
evidence of ischemia one year after revascularization were
asymptomatic and, after three years, 29% had an MI and/or
died. In contrast, only 14% of PCI patients without isch-
emia had a cardiac event at three years.
Table 4. Accuracy of Myocardial SPECT Imaging Following Percutaneous Coronary Intervention
Author (Ref.) Year
No. of
Patients
PCI
Modality
% With
Angina
Mean Time
to SPECT
Mean Time
to Angiogram Sens % Spec % Acc %
Hecht et al. (15) 1991 116 PTCA 65 6 months 1 week 93 77 86
41* 0 96* 75* 88*
75† 100 91† 77† 85†
Marie et al. (37) 1993 62* PTCA 0 6 months 3 days 94* 84* 87*
Milan et al. (54)‡ 1996 37 PTCA N/A “late” 1 month 88 78 83
20§ 92§ 67§ N/A
Ko´sa et al. (55) 1998 82 (99) Stenting N/A 7 months 1 month 79 78 79
35 (52)§ N/A 100§ 82§ 85§
Milavetz et al. (56) 1998 33 Stenting 64 3 months 5 days 71 — 67
95¶ 73¶ 88¶
Caner et al. (57)# 1998 34 (37) PTCA N/A 2–48 months 1 month 76 79 78
Beygui et al. (58) 2000 179 (208)* PTCA 0 6 months 7 days 63* 77* 71*
111 (138) 56§ 81§ 74§
Galassi et al. (59) 2000 97 (107) Stenting N/A 4 months 2 months 82** 84** 83**
46 (56)§ 76§ 95§ 89§
Overall performance of SPECT MPI 79†† 79†† 79††
Number of treated territories are indicated in parentheses; restenosis is defined as 50% diameter stenosis unless otherwise indicated; *patients with “silent” ischemia; †patients
with “symptomatic” ischemia; ‡all patients referred because of “equivocal” exercise stress tests, values reported are for qualitative analyses; §patients without prior infarction;
calculations using 50% cross-sectional area narrowing definition; ¶calculations using 70% cross-sectional area narrowing definition; #dobutamine stress used for all patients;
**calculations based upon vascular territories; ††weighted average.
MPImyocardial perfusion imaging; PCI percutaneous coronary intervention; SPECT single-photon emission computed tomography. Other abbreviations as in Tables
1 and 3.
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IMPACT OF REINTERVENTION ON PROGNOSIS
Data addressing the effects of reintervention on the prog-
nosis of patients with restenosis are scarce. In the study of
Herna´ndez et al. (16), none of the 18 patients with
asymptomatic restenosis and a positive or nondiagnostic
stress test who underwent “elective” reintervention had a
cardiac event over the ensuing 17 months. In contrast, of the
29 asymptomatic patients with positive stress tests who were
treated medically, 21% developed recurrent angina.
Pfisterer et al. (36) studied 109 patients with angio-
graphic restenosis and ischemia on MPI six months follow-
ing PTCA. At two-year follow-up there was a trend toward
a lower event rate (cardiac death, MI, revascularization, or
hospital admission) in patients who underwent reinterven-
tion compared with those who did not (5% vs. 15%; p 
NS), despite the presence of more ominous prognostic
indicators in patients undergoing reintervention. Among
patients with silent ischemia, the event rate was significantly
lower in those who underwent reintervention than in those
who did not (14% vs. 44%; p  0.05). The event rate was
also lower in a parallel asymptomatic cohort without isch-
emia than in patients with silent ischemia who did not
undergo reintervention (27% vs. 44%; p  0.02).
In the study of Zellweger et al. (38), 16 patients with
target vessel ischemia underwent early MPI-driven repeat
revascularization. These patients tended to have more severe
and extensive ischemia than those patients with ischemia
included in the “prognostic patient” group. Nonetheless,
they had a favorable outcome. Although the numbers of
patients were too small to permit statistical comparison, the
four-year cumulative event rate was 29% for the 17 patients
who underwent MPI-driven revascularization (16 with tar-
get vessel ischemia and 1 with no ischemia), whereas the
overall event rate was 38% for patients with target-vessel
ischemia included in the prognostic patient group, with
event rates of 29% and 69%, respectively, for those with
mild and moderate-to-severe ischemia.
CONCLUSIONS AND RECOMMENDATIONS
Coronary atherosclerosis is a chronic disease. Despite excel-
lent short-term benefits, PCI does not confer long-term
immunity from adverse cardiac events. Whereas chest pain
Figure 1. Treatment algorithm following percutaneous coronary intervention (PCI). If patients undergo repeat PCI, they are treated as though it was their
first intervention. If repeat coronary angiography shows no evidence of restenosis or progression of disease elsewhere, patients should have clinical follow-up
and undergo single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI) in two years. If patients develop chest pain, they
should undergo SPECT MPI if unstable angina is not present and coronary angiography if pain is accompanied by electrocardiographic changes or release
of cardiac enzymes. *Increased risk of restenosis (see Table 2); †no factors listed in Table 2 present. CABG  coronary artery bypass grafting.
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is a poor indicator of ischemia and does not risk-stratify
patients following revascularization, MPI does. Current
guidelines (29,42,43) recognize that myocardial ischemia
worsens prognosis, whether manifest or asymptomatic.
However, routine testing of patients after PCI is not
recommended because “the prognostic benefit of controlling
silent ischemia needs to be proved” (42) and because there is
“a lack of data that outcomes are affected by this approach”
(43).
Clearly what is needed is a prospective randomized study
assessing the efficacy of routine noninvasive testing and
directed reintervention to optimize management of the
increasing number of patients undergoing PCI. In the
interim, we believe that the preponderance of the evidence
currently available demonstrates a benefit to routine screening
with MPI and directed reintervention, when appropriate.
Given the high false-positive rate, there is little role for
MPI early (3 months) after PCI. To most efficaciously
manage patients who develop chest pain within three
months of revascularization, angiography should be per-
formed (Fig. 1). Between three and six months, patients
with typical angina, ECG changes, or elevated cardiac
enzymes should also undergo angiography. Patients with
atypical symptoms having characteristics associated with an
increased likelihood of restenosis (Table 2) should undergo
angiography as well. Patients lacking such characteristics
who develop atypical symptoms should undergo MPI.
Although the specificity of MPI three to six months
following PCI is diminished, normal perfusion reliably
excludes restenosis. If perfusion is abnormal, angiography
should be performed.
The accuracy of MPI performed six or more months
following PCI is excellent (Table 4). We believe that
following PCI, asymptomatic patients should initially be
followed clinically and undergo MPI at six to nine months.
Patients with normal, low-risk, or intermediate-risk scans
(small or medium-sized defects of mild-to-moderate sever-
ity) can be managed medically. Patients with high-risk scans
(medium-sized severe defects, large defects of any severity,
or scans showing stress-induced left ventricular failure)
should undergo angiography.
Thereafter, asymptomatic PCI patients should undergo
MPI every one to three years. This recommendation is
based on the study of Hachamovitch et al. (12), who
determined that the time to a 1.5% predicted risk of cardiac
death or nonfatal MI in most patients with known CAD
and a normal index MPI ranges from 0.9 to 2.5 years. If
symptoms develop, MPI should be performed sooner. Most
patients presenting with acute coronary syndromes should
be managed invasively.
Developments in the percutaneous treatment of CAD
made over the past two decades should be paralleled by
similar advances in the ongoing care of patients after
revascularization. The benefits obtained through PCI
should be complemented by a sound follow-up strategy.
This includes implementation of lifestyle modifications,
such as smoking cessation, appropriate dietary changes,
weight loss, and regular exercise; optimal control of blood
pressure and serum glucose; and use of angiotensin-
converting enzyme inhibitors, antiplatelet agents, beta-
blockers, and lipid-lowering agents when indicated. In
addition, MPI can accurately identify patients at greatest
risk of adverse cardiac events following PCI. Together with
other standard-of-care secondary prevention strategies, rou-
tine MPI and directed reintervention will likely have an
incremental benefit on the long-term outcome of patients
after percutaneous revascularization.
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